8 results match your criteria: "The James Comprehensive Cancer Center at The Ohio State University[Affiliation]"
Gynecol Oncol Rep
August 2024
The James Comprehensive Cancer Center at The Ohio State University, Department of Gynecologic Oncology, United States.
Int J Radiat Oncol Biol Phys
November 2024
Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian, New York, New York. Electronic address:
Purpose: The role of stereotactic radiosurgery (SRS) in the management of grade 2 and 3 meningiomas is not well elucidated. Unfortunately, local recurrence rates are high, and guidelines for management of recurrent disease are lacking. To address this knowledge gap, we conducted STORM (Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas), a multicenter retrospective cohort study of patients treated with primary SRS for recurrent grade 2 and 3 meningiomas.
View Article and Find Full Text PDFJ Natl Cancer Inst
August 2023
Katsuta Hospital Mito GammaHouse, Hitachi-naka, Japan.
Cancer
October 2022
Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Adv Exp Med Biol
December 2020
Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital and The James Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA.
Outcomes for young people diagnosed with osteosarcoma hinge almost exclusively on whether they develop lung metastasis. The striking predilection that osteosarcoma shows for metastatic spread to lung suggests properties and/or lung interactions that generate tissue-specific survival and proliferation advantages. While these mechanisms remain overall poorly defined, studies have begun to describe biological elements important to metastasis.
View Article and Find Full Text PDFFront Oncol
January 2020
Poul Sorensen Laboratory, Department of Molecular Oncology, BC Cancer, Part of the Provincial Health Services Authority in British Columbia, Vancouver, BC, Canada.
Osteosarcoma is a malignant primary tumor of bone, arising from transformed progenitor cells with osteoblastic differentiation and osteoid production. While categorized as a rare tumor, most patients diagnosed with osteosarcoma are adolescents in their second decade of life and underscores the potential for life changing consequences in this vulnerable population. In the setting of localized disease, conventional treatment for osteosarcoma affords a cure rate approaching 70%; however, survival for patients suffering from metastatic disease remain disappointing with only 20% of individuals being alive past 5 years post-diagnosis.
View Article and Find Full Text PDFJ Oncol Pharm Pract
January 2020
Department of Pharmacy, Charles F. Kettering Medical Center, Kettering, OH, USA.
Purpose: As immune checkpoint inhibitors continue to acquire new indications, it is important to understand the impact their use has on patients. This study adds to current literature by presenting an analysis of hospitalizations in this population. The primary objective was to assess the reasons for an emergency department visit or hospital admission in patients who receive immune checkpoint inhibitors.
View Article and Find Full Text PDFClin Colorectal Cancer
September 2016
Department of Pharmacy, The James Comprehensive Cancer Center at The Ohio State University, Columbus, OH. Electronic address: